Allonnia just pulled in another $20M+ to extend its Series A, and it feels like watching a biotech turntable finally hit club volume. The company built on the belief that waste still has untapped value is stepping into its commercial era with the kind of momentum that makes even the quiet investors clear their throats. Viking Global Investors, Bison Ventures, General Atlantic, BHP Ventures, and Pivotal Capital Partners did not gather around this round for a sightseeing tour. They backed a team led by CEO Nicole Richards and CTO Kent Sorenson that has shown it can turn biology into an industrial force multiplier instead of a science fair project with good intentions.
The proof is already on the board. At SGS Lakefield, a 5 day continuous run on nickel sulfide concentrate cut magnesium impurities by 40% and boosted nickel grade by 18%, all using recyclable biosolutions that behaved more like seasoned craftsmen than chemicals on a tear. Those numbers alone can shift mine economics, which is why the upcoming deployment of the mobile D Solve unit at Eagle Mine in Michigan’s Upper Peninsula is more than a field test. Processing 1 to 2 tonnes of concentrate a day is a declaration that bio selective separation is leaving the lab and entering payroll.
But Allonnia is not a single hit act. SAFF has already treated 4M+ gallons of PFAS contaminated water and now tackles short chain compounds. The 1,4 Dioxane D Stroy tech wipes out 99% of a notoriously stubborn carcinogenic contaminant, turning it into H2O and CO2 like it is rewriting the rules of cleanup kinetics. The PFAS biosensor that detects parts per trillion feels like a new superhero origin story, one built on proteins instead of capes. These products form a portfolio aligned with an economy that no longer has room for waste as an afterthought.
The leadership bench reads like a company preparing for scale rather than survival mode. Nicole Richards steering strategy with decades of industrial depth. Kent Sorenson grounding the tech with global remediation authority. Chuck Price turning innovation into traction. Hugh Merryweather shaping financial discipline. Dayal Saran running research with biochemical precision. The board, including Marc Doyle, Michael Silvestro, Dean Gehring, and Thomas Bostick, adds perspectives forged in mining, national security, biotechnology and global operations.
What makes this raise compelling is not the capital but the alignment. As critical mineral demand accelerates and PFAS remediation becomes unavoidable, the market is rewarding companies that see constraint as catalyst. Allonnia is proving that biology can clean, separate and recover with a grace industrial methods have chased for decades. If this is what $100M+ of conviction looks like, the next chapter will not just be watched. It will be studied.
Startups Startup Funding Venture Capital Series A Biotech Environmental Tech Climate Tech Clean Tech Technology Innovation Tech Ecosystem Startup Ecosystem
